Phentermine
Phentermine structure
|
Common Name | Phentermine | ||
|---|---|---|---|---|
| CAS Number | 122-09-8 | Molecular Weight | 149.233 | |
| Density | 0.9±0.1 g/cm3 | Boiling Point | 206.0±0.0 °C at 760 mmHg | |
| Molecular Formula | C10H15N | Melting Point | 143°C (estimate) | |
| MSDS | N/A | Flash Point | 93.1±9.3 °C | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Recent advancements in drug treatment of obesity.
Clin. Med. 12(5) , 456-60, (2012) The prevalence of obesity is rising worldwide, with the U.K. having the highest prevalence in Europe. Obesity is associated with significant morbidity and has substantial healthcare implications, with current projections estimating that by 2030 obesity will c... |
|
|
Off-label medication use.
J. Psychosoc. Nurs. Ment. Health Serv. 50(9) , 11-3, (2012) Prescribing medications for off-label uses is not illegal. Off-label prescribing includes using medications for unapproved indications; using a drug outside of the recommended dosage range or duration of use; using a drug in certain unapproved patient populat... |
|
|
Therapies for obesity and medication-associated weight gain.
J. Psychosoc. Nurs. Ment. Health Serv. 51(5) , 13-6, (2013) Compared to the general population, individuals with psychiatric illness, especially serious and chronic mood and psychotic disorders, are more likely to be overweight or obese, have higher rates of weight-related medical conditions, and have greater non-suic... |
|
|
Phentermine/topiramate for the treatment of obesity.
Ann. Pharmacother. 47(3) , 340-9, (2013) To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients.MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine, topiramate, Qnexa, Q... |
|
|
Obesity drug therapy.
Minerva Endocrinol. 38(3) , 245-54, (2013) Obesity is a chronic disease, and it requires chronic therapy. Hypertension, dyslipidemia, diabetes and cardiovascular diseases are leading causes of mortality in the modern world. All of them are strongly linked to obesity. While treating obesity, those cond... |
|
|
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
JAMA Intern. Med. 174(4) , 615-9, (2014) In 2012, the US Food and Drug Administration approved 2 drugs for long-term weight loss: lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine-topiramate (Qysmia; Vivus Inc). The approvals were based on 1-year trials showing that on top of recommendati... |
|
|
Appetite suppressants in pregnancy.
Neuro Endocrinol. Lett. 33 Suppl 3 , 179-82, (2012) Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the u... |
|
|
Is it worth the weight?
Anaesth. Intensive Care 41(4) , 553-4, (2013)
|
|
|
Spontaneous pneumomediastinum and "diet pills": an association?
Am. J. Respir. Crit. Care Med. 187(8) , 893-4, (2013)
|
|
|
Unambiguous identification of obesity trials.
N. Engl. J. Med. 368(6) , 580-1, (2013)
|